Kelun-Biotech’s Sac-TMT Plus Keytruda Hits Phase III Endpoint in PD-L1-Positive NSCLC Trial

Reuters11-24

Kelun-Biotech's Sac-TMT Plus Keytruda Hits Phase III Endpoint in PD-L1-Positive NSCLC Trial

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced that its Phase III clinical trial (OptiTROP-Lung05) evaluating sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) in combination with KEYTRUDA® (pembrolizumab) as a first-line treatment for PD-L1-positive advanced non-small cell lung cancer (NSCLC) has met its primary endpoint. The Independent Data Monitoring Committee reported a statistically significant and clinically meaningful improvement in progression-free survival $(PFS)$, with a positive trend in overall survival also observed. This marks the first Phase III clinical trial of an antibody-drug conjugate combined with an immune checkpoint inhibitor to achieve its primary endpoint in first-line NSCLC treatment. The results have already been concluded as of the announcement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN31787) on November 24, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2585461585?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-24 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2585461585","market":"nz","top_or_hot":-1,"title":"Kelun-Biotech’s Sac-TMT Plus Keytruda Hits Phase III Endpoint in PD-L1-Positive NSCLC Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Kelun-Biotech's Sac-TMT Plus Keytruda Hits Phase III Endpoint in PD-L1-Positive NSCLC Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/002422\">Sichuan Kelun</a>-Biotech Biopharmaceutical Co., Ltd. announced that its Phase III clinical trial (OptiTROP-Lung05) evaluating sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) in combination with KEYTRUDA® (pembrolizumab) as a first-line treatment for PD-L1-positive advanced non-small cell lung cancer (NSCLC) has met its primary endpoint. The Independent Data Monitoring Committee reported a statistically significant and clinically meaningful improvement in progression-free survival <a href=\"https://laohu8.com/S/PFS\">$(PFS)$</a>, with a positive trend in overall survival also observed. This marks the first Phase III clinical trial of an antibody-drug conjugate combined with an immune checkpoint inhibitor to achieve its primary endpoint in first-line NSCLC treatment. The results have already been concluded as of the announcement.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN31787) on November 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kelun-Biotech’s Sac-TMT Plus Keytruda Hits Phase III Endpoint in PD-L1-Positive NSCLC Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKelun-Biotech’s Sac-TMT Plus Keytruda Hits Phase III Endpoint in PD-L1-Positive NSCLC Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-24 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Kelun-Biotech's Sac-TMT Plus Keytruda Hits Phase III Endpoint in PD-L1-Positive NSCLC Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/002422\">Sichuan Kelun</a>-Biotech Biopharmaceutical Co., Ltd. announced that its Phase III clinical trial (OptiTROP-Lung05) evaluating sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) in combination with KEYTRUDA® (pembrolizumab) as a first-line treatment for PD-L1-positive advanced non-small cell lung cancer (NSCLC) has met its primary endpoint. The Independent Data Monitoring Committee reported a statistically significant and clinically meaningful improvement in progression-free survival <a href=\"https://laohu8.com/S/PFS\">$(PFS)$</a>, with a positive trend in overall survival also observed. This marks the first Phase III clinical trial of an antibody-drug conjugate combined with an immune checkpoint inhibitor to achieve its primary endpoint in first-line NSCLC treatment. The results have already been concluded as of the announcement.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN31787) on November 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1934453819.USD","symbol_name":"AB CHINA A SHARES EQUITY PORTFOLIO \"A\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL5cqhCb:1","article_id":"2585461585","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2585461585","pubTimestamp":1763985636,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced that its Phase III clinical trial  evaluating sacituzumab tirumotecan  in combination with KEYTRUDA  as a first-line treatment for PD-L1-positive advanced non-small cell lung cancer  has met its primary endpoint. The Independent Data Monitoring Committee reported a statistically significant and clinically meaningful improvement in progression-free survival , with a positive trend in overall survival also observed. This marks the first Phase III clinical trial of an antibody-drug conjugate combined with an immune checkpoint inhibitor to achieve its primary endpoint in first-line NSCLC treatment. The results have already been concluded as of the announcement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, i","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1934453819.USD":"AB CHINA A SHARES EQUITY PORTFOLIO \"A\" (USD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","06990":"科伦博泰生物-B","LU0196878994.USD":"MANULIFE GF CHINA VALUE \"AA\" (USD) INC","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU1979443071.USD":"AB CHINA A SHARES EQUITY PORTFOLIO \"AD\" (USDHDG) INC","BK0239":"医药制造","BK1161":"生物科技","002422":"科伦药业","BK0060":"抗癌"},"translate_title":"科伦生物Sac-TMT加Keytruda在PD-L1阳性非小细胞肺癌试验中达到III期终点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"002422":0.9,"06990":0.9},"content_text":"Kelun-Biotech's Sac-TMT Plus Keytruda Hits Phase III Endpoint in PD-L1-Positive NSCLC Trial\n    \n\nSichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced that its Phase III clinical trial (OptiTROP-Lung05) evaluating sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) in combination with KEYTRUDA® (pembrolizumab) as a first-line treatment for PD-L1-positive advanced non-small cell lung cancer (NSCLC) has met its primary endpoint. The Independent Data Monitoring Committee reported a statistically significant and clinically meaningful improvement in progression-free survival $(PFS)$, with a positive trend in overall survival also observed. This marks the first Phase III clinical trial of an antibody-drug conjugate combined with an immune checkpoint inhibitor to achieve its primary endpoint in first-line NSCLC treatment. The results have already been concluded as of the announcement.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN31787) on November 24, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2585461585","isCrawlerRequest":true}